Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs.

ABSTRACT: The development of efficacious antitumor compounds with minimal toxicity is a hot research topic. Numerous cancer cell targeted agents are evaluated daily in laboratories for their antitumorigenicity at the pre-clinical level, but the process of their introduction into the market is costly and time-consuming. More importantly, even if these new antitumor agents manage to gain approval, clinicians have no former experience with them. Accruing evidence supports the idea that several medications already used to treat pathologies other than cancer display pleiotropic effects, exhibiting multi-level anti-cancer activity and chemosensitizing properties. This review aims to present the anticancer properties of marketed drugs (i.e., metformin and pioglitazone) used for the management of diabetes m

SUBMITTER: Papanagnou P 

PROVIDER: S-EPMC4932542 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature